Shots: CRISPR to receive $900M up front with an additional $200M milestone upon the regulatory approval of CTX001. Vertex will responsible for the global development, manufacturing, and commercialization of CTX001 […]readmore
Tags : Manufacturing
Shots: mAbxience will equip their state-of-the-art cGMP facility in Spain with an ABEC 4,000L CSR Bioreactor The system will be commissioned mid-2021 and will increase biosimilar and CDMO manufacturing capacity […]readmore
Shots: WuXi Biologics signs an equity agreement with Pfizer to acquire its state-of-the-art biologics manufacturing facilities along with its labor force in Hangzhou, China. The transaction is expected to close […]readmore
Shots: The companies signed an agreement to manufacture movantik for opioid-induced constipation and RHB-204, currently in a P-III US study as a stand-alone 1L treatment for pulmonary NTM disease Movantik […]readmore
Shots: Emergent will provide CDMO services for AstraZeneca’ AZD1222. The agreement valued ~174M through 2021 and follows an $87M agreement signed in June for development services, performance and process qualification, […]readmore
Biotech
Samsung Biologics Signs Multi-Product Development and Manufacturing Agreement with ImmuneOncia
Shots: The two companies expand their 2018 agreement to develop and manufacture five candidates from ImmuneOncia’s pipeline. The partners expand the collaboration to bring new treatments such as IMC-002 for […]readmore
Shots: Emergent will be responsible to provide large-scale drug substance for manufacturing Janssen’s Ad26.COV2-S for the first two years valued at ~$480M in 2021. Additionally, at the beginning of 2023 […]readmore
Shots: The companies collaborated to provide GSK with additional capacity to manufacture and supply GSK’s innovative biopharmaceutical therapies. The eight-year contract is valued at more than $231M This capacity will […]readmore
Shots: Janssen partnered with Emergent to develop more than a billion doses of a COVID-19 vaccine candidate, as it anticipates scaling up global manufacturing of its potential treatment. The agreement […]readmore
Shots: The approval will increase the production capacity of Ruconest and allows Pharming to release the therapy manufactured at the facility during the approval process for commercialization in the EU […]readmore